Please login to the form below

Not currently logged in
Email:
Password:

Ex-GSK CEO Jean-Pierre Garnier takes up role at Alzheon

He will be the US biopharma's chairman of board of directors

Alzheon Jean-Pierre GarnierFormer GlaxoSmithKline chief executive Jean-Pierre Garnier has been appointed chairman of board of directors at US-based clinical-stage biopharmaceutical company Alzheon.

The firm focuses on brain health, memory and ageing and its lead product is an oral amyloid aggregation inhibitor that targets Alzheimer's disease.

Alzheon's founder, president and chief executive officer Martin Tolar said: “JP will provide invaluable insights and guidance as we advance our lead oral amyloid aggregation inhibitor, ALZ-801, into a phase III clinical programme targeting a genetically-defined Alzheimer's disease population, and execute on our long-term strategy to bring innovative therapies to patients with neurodegenerative disorders.”

Garnier served as SmithKline Beecham's chief executive officer, having joined the company in 1990 as president of pharmaceuticals for North America.

He subsequently became GSK's first CEO following its formation from the merger of Glaxo Wellcome and SmithKline Beecham in 2001 and he held that position until in 2008.

Garnier then became chief executive officer of Pierre Fabre Laboratories and chairman of biotechnology company Cerenis.

He is currently chairman of the board of directors for Swiss biopharmaceutical company Actelion.

11th December 2015

From: Research

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
90TEN

90TEN is a global healthcare communications consultancy with a mission to make people healthier and happier through life-changing education and...

Latest intelligence

What does the future hold for Light-chain Amyloidosis?
Recent advances in the understanding and treatment are reforming pharma’s approach to the management of this rare disease. With a new standard of care rapidly developing, what does the landscape...
Webinar:
Securing a future for telehealth with immersive market research insights...
Accelerating patient recruitment in clinical trials with the Clinical Enrolment Managers (CEMs)
How Innovative Trials' global Clinical Enrolment Managers (CEMs) give clinical trial sites the local touch...